SYMPTOMATIC ANEMIA DURING CANCER CHEMOTHERAPY- rhERYTHROPIETIN (rhEPO) AND QUALITY OF LIFE

Author(s)

Bonicatto S, Giacomi N, Ferreras R, De la Cruz J, Cichetti G, Gelemur M, Riva M, Ivulich C, Ferreyra L, Fundaci n FUNDONAR, la Plata, Bosas, Argentina

In light of the current emphasis in the health care environment on both minimising cost and maximising favorable outcomes, it makes good economic sense to incorporate quality of life (QOL) assessment in order to sensitively evaluate the impact of interventions on individual s well being. The aim of the study was to determine to what extent QOL is influenced by the Hb increase and if, in this way, patients who showed improved Hb levels also showed improvements in QOL domains. 26 anemic cancer patients undergoing chemotherapy with initial Hb levels

Conference/Value in Health Info

2000-05, ISPOR 2000, Arlington, VA, USA

Value in Health, Vol. 3, No. 2 (March/April 2000)

Code

PCN11

Topic

Epidemiology & Public Health

Topic Subcategory

Safety & Pharmacoepidemiology

Disease

Oncology

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×